CA2912133C - Cxcr7 receptor modulators - Google Patents

Cxcr7 receptor modulators Download PDF

Info

Publication number
CA2912133C
CA2912133C CA2912133A CA2912133A CA2912133C CA 2912133 C CA2912133 C CA 2912133C CA 2912133 A CA2912133 A CA 2912133A CA 2912133 A CA2912133 A CA 2912133A CA 2912133 C CA2912133 C CA 2912133C
Authority
CA
Canada
Prior art keywords
ethyl
tetrahydro
isoquinolin
acetamide
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2912133A
Other languages
English (en)
French (fr)
Other versions
CA2912133A1 (en
Inventor
Heinz Fretz
Philippe Guerry
Thierry Kimmerlin
Francois LEHEMBRE
Julien Pothier
Herve Siendt
Anja Valdenaire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idorsia Pharmaceuticals Ltd
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CA2912133A1 publication Critical patent/CA2912133A1/en
Application granted granted Critical
Publication of CA2912133C publication Critical patent/CA2912133C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
CA2912133A 2013-05-30 2014-05-28 Cxcr7 receptor modulators Active CA2912133C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2013054478 2013-05-30
IBPCT/IB2013/054478 2013-05-30
PCT/IB2014/061774 WO2014191929A1 (en) 2013-05-30 2014-05-28 Cxcr7 receptor modulators

Publications (2)

Publication Number Publication Date
CA2912133A1 CA2912133A1 (en) 2014-12-04
CA2912133C true CA2912133C (en) 2021-06-22

Family

ID=50943357

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2912133A Active CA2912133C (en) 2013-05-30 2014-05-28 Cxcr7 receptor modulators

Country Status (30)

Country Link
US (1) US9920010B2 (cg-RX-API-DMAC10.html)
EP (1) EP3004082B1 (cg-RX-API-DMAC10.html)
JP (1) JP6393749B2 (cg-RX-API-DMAC10.html)
KR (1) KR102302580B1 (cg-RX-API-DMAC10.html)
CN (1) CN105263924B (cg-RX-API-DMAC10.html)
AR (1) AR096490A1 (cg-RX-API-DMAC10.html)
AU (1) AU2014272718B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015030095B1 (cg-RX-API-DMAC10.html)
CA (1) CA2912133C (cg-RX-API-DMAC10.html)
CL (1) CL2015003470A1 (cg-RX-API-DMAC10.html)
CY (1) CY1119537T1 (cg-RX-API-DMAC10.html)
DK (1) DK3004082T3 (cg-RX-API-DMAC10.html)
EA (1) EA028604B1 (cg-RX-API-DMAC10.html)
ES (1) ES2645470T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20171597T1 (cg-RX-API-DMAC10.html)
HU (1) HUE036649T2 (cg-RX-API-DMAC10.html)
IL (1) IL242782B (cg-RX-API-DMAC10.html)
LT (1) LT3004082T (cg-RX-API-DMAC10.html)
MA (1) MA38679B1 (cg-RX-API-DMAC10.html)
MX (1) MX364104B (cg-RX-API-DMAC10.html)
MY (1) MY173564A (cg-RX-API-DMAC10.html)
NO (1) NO3004082T3 (cg-RX-API-DMAC10.html)
PH (1) PH12015502632B1 (cg-RX-API-DMAC10.html)
PL (1) PL3004082T3 (cg-RX-API-DMAC10.html)
PT (1) PT3004082T (cg-RX-API-DMAC10.html)
SG (1) SG11201509057UA (cg-RX-API-DMAC10.html)
SI (1) SI3004082T1 (cg-RX-API-DMAC10.html)
TW (1) TWI640510B (cg-RX-API-DMAC10.html)
UA (1) UA118562C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014191929A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
US10202368B2 (en) 2014-12-01 2019-02-12 Idorsia Pharmaceuticals Ltd. CXCR7 receptor modulators
US20170112831A1 (en) * 2015-10-23 2017-04-27 James MERRITT Use of ccr1 antagonists as a treatment for tumors of the central nervous system
EP3490986B1 (en) * 2016-07-28 2021-11-24 Idorsia Pharmaceuticals Ltd Piperidine cxcr7 receptor modulators
AR111808A1 (es) 2017-05-18 2019-08-21 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EA201992676A1 (ru) 2017-05-18 2020-05-06 Идорсия Фармасьютиклз Лтд Фенильные производные в качестве модуляторов pge2 рецепторов
KR102502046B1 (ko) 2018-01-26 2023-02-20 이도르시아 파마슈티컬스 리미티드 Cxcr7 수용체 작동제 (3s,4s)-1-시클로프로필메틸-4-{[5-(2,4-디플루오로-페닐)-이속사졸-3-카르보닐]-아미노}-피페리딘-3-카르복실산 (1-피리미딘-2-일-시클로프로필)-아미드의 결정질 형태

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896170A (en) 1969-02-26 1975-07-22 American Home Prod Intermediates for the preparation of 1,3-dihydro-2h-1, -benzodiazepin-2-ones
RU2214405C2 (ru) 1998-02-18 2003-10-20 НьюроСёрч А/С Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов
GB9816984D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US7256201B2 (en) 2000-12-07 2007-08-14 Astrazeneca Ab Selective estrogen receptor-β ligands
ATE427933T1 (de) 2002-12-20 2009-04-15 Chemocentryx Inc Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
ATE486875T1 (de) * 2005-11-10 2010-11-15 Chemocentryx Inc Substituierte chinolone und verwendungsverfahren
US20100331298A1 (en) 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
AR091516A1 (es) * 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
US10202368B2 (en) 2014-12-01 2019-02-12 Idorsia Pharmaceuticals Ltd. CXCR7 receptor modulators

Also Published As

Publication number Publication date
PH12015502632A1 (en) 2016-03-07
MY173564A (en) 2020-02-04
LT3004082T (lt) 2017-10-25
EA028604B1 (ru) 2017-12-29
MA38679B1 (fr) 2019-12-31
PT3004082T (pt) 2017-11-13
HUE036649T2 (hu) 2018-07-30
SG11201509057UA (en) 2015-12-30
US9920010B2 (en) 2018-03-20
KR20160013197A (ko) 2016-02-03
AU2014272718B2 (en) 2018-06-28
BR112015030095B1 (pt) 2023-02-28
JP6393749B2 (ja) 2018-09-19
AU2014272718A1 (en) 2016-01-21
DK3004082T3 (en) 2017-10-02
WO2014191929A1 (en) 2014-12-04
CN105263924B (zh) 2018-10-19
EP3004082A1 (en) 2016-04-13
ES2645470T3 (es) 2017-12-05
EA201501163A1 (ru) 2016-06-30
CY1119537T1 (el) 2018-03-07
IL242782A0 (en) 2016-02-01
PL3004082T3 (pl) 2018-01-31
US20160107997A1 (en) 2016-04-21
NZ715530A (en) 2020-12-18
HK1223353A1 (en) 2017-07-28
NO3004082T3 (cg-RX-API-DMAC10.html) 2017-12-30
CL2015003470A1 (es) 2016-06-17
TW201529557A (zh) 2015-08-01
EP3004082B1 (en) 2017-08-02
UA118562C2 (uk) 2019-02-11
MA38679A1 (fr) 2018-07-31
AR096490A1 (es) 2016-01-13
MX2015016429A (es) 2016-03-01
BR112015030095A2 (pt) 2022-07-12
IL242782B (en) 2019-06-30
MX364104B (es) 2019-04-12
KR102302580B1 (ko) 2021-09-15
HRP20171597T1 (hr) 2017-12-01
SI3004082T1 (sl) 2017-11-30
CN105263924A (zh) 2016-01-20
JP2016520120A (ja) 2016-07-11
PH12015502632B1 (en) 2016-03-07
TWI640510B (zh) 2018-11-11
CA2912133A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
DK3004082T3 (en) CXCR7 RECEPTOR MODULATORS
CN107406426B (zh) 作为rock抑制剂的环状脲类
KR101646858B1 (ko) 아제티딘 화합물, 조성물 및 가용성 에폭사이드 가수분해효소의 억제제로서의 이의 용도
EP3227263B1 (en) Cxcr7 receptor modulators
US20040242613A1 (en) Pyrimidine derivatives useful as inhibitors of PKC-theta
JP2009529566A (ja) スピロインドリノン誘導体
JP2009530236A (ja) スピロインドリノン誘導体
RS55866B1 (sr) Proces za dobijanje derivata piperazinil i diazepanil benzamida
KR20110008085A (ko) 헤테로사이클릭 화합물
KR20060123415A (ko) 신규한 m3 무스카린성 아세틸콜린 수용체 길항제
US20120258957A1 (en) Heterocyclic derivatives
JP2022509434A (ja) 疼痛に対して活性があるピペラジニル及びピペリジニルキナゾリン-4(3h)-オン誘導体
NZ715530B2 (en) Cxcr7 receptor modulators
HK1223353B (en) Cxcr7 receptor modulators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190418

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260320

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260323

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260619

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260804